Emergency Med

Your Article Summary

See Latest Articles

Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine
Cephalalgia, 09/08/09

Silberstein SDe et al. – Tonabersat was generally well tolerated, with dizziness and nausea the most common side–effects. Serious adverse events were uncommon, and no patient withdrew from either study because of adverse events. These results suggest a possible interplay between tonabersat pharmacokinetics (the relatively long time required to reach maximum plasma concentrations) and patient characteristics (previous triptan exposure) in the management of acute migraine attacks. Based on the pharmacokinetics and actions on cortical spreading depression, tonabersat may have potential value in migraine prophylaxis.

Today in Neurology/Neurosurgery...keeping you current

Receive free subspecialty "5-minute updates" via email

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Migraine Chronification - Concept and Risk Factors
Discovery Medicine, 10/27/09

Stroke treatment with alteplase given 3·0—4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial
The Lancet Neurology, 11/17/09

See All of Neurology/Neurosurgery

Today in Pain Management...keeping you current

Receive free subspecialty "5-minute updates" via email

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Migraine Chronification - Concept and Risk Factors
Discovery Medicine, 10/27/09

Acute back pain: benefits and risks of current treatments
Current Medical Research and Opinion, 11/19/09

See All of Pain Management